Site Search
Results
-
Minutes: BSC; May 24, 2000
... synthetic oligonucleotides (antisense therapies and adjuvants), and viral based vectors ... 2000 third world countries of providing cheap vaccines that could be disseminated widely. ...
Size: 495KB https://ntp.niehs.nih.gov/sites/default/files/ntp/about_ntp/bsc/archives/2000/may/2000052400bscsummmins_508.pdf -
IMACS Studies
myositis by discovering better therapies and understanding the causes of these diseases. ... about given patients, their clinical and laboratory features, and therapies received. ...
https://www.niehs.nih.gov/research/resources/imacs/imacsstudies -
Partnering With NIEHS
Research in NIEHS laboratories and branches lead to discoveries and innovations in various subject areas from cutting edge toxicological tools to therapies and diagnostics related ...
https://www.niehs.nih.gov/research/resources/techtransfer/partnering -
International Myositis Assessment and Clinical Studies Group (IMACS)
by discovering better therapies through understanding the causes of these diseases. ... therapeutic trials of targeted biologic therapies in patients with adult and juvenile ...
https://www.niehs.nih.gov/research/resources/imacs -
Placental Cell Biology Group
Failure or dysregulation of these pathways could explain the origin of several placental disorders, but also provide a window for new therapies. Inactivation of autophagy genes in ...
https://www.niehs.nih.gov/research/atniehs/labs/rdbl/pi/placental-cell -
Disease Damage Core Set Measures
IMACS has developed a consensus that damage should be present at least 6 months despite prior immunosuppressive, rehabilitation or other therapies. The preliminary core set ...
https://www.niehs.nih.gov/research/resources/imacs/diseasedamage -
IMACS Annual Meeting 2008
Frederick Miller 0715 - 0830 Minisymposium - Biologic Therapies in Myositis: Current ... Ingrid Lundberg 3. Rituximab and other B cell Therapies Dr. Chester Oddis 4. ...
https://www.niehs.nih.gov/research/resources/imacs/news_main/news_item08oct27 -
Preventing Disease Through Bioinformatics
There, he explored the genetic mechanisms that lead to cancer to identify targets for improved therapies. As he dove into cancer research, Monti recognized an imbalance in the ...
https://www.niehs.nih.gov/research/supported/success/2022/monti -
Benedict Anchang, Ph.D.
This method models drug effects while accounting for tumor complexity, paving the way for individualized therapies. Currently, his research also explores how ancestry, maternal ...
https://www.niehs.nih.gov/research/atniehs/labs/bcb/staff/anchang -
Environmental Autoimmunity Group
pathogenesis, and the development of tools for the assessment of innovative therapies. ... Developing new assessments and novel therapies for myositis Current projects: ...
https://www.niehs.nih.gov/research/atniehs/labs/crb/pi/ea
to Top